Elanco Animal Health INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NYSE
Michael J Harrington, a Director of Elanco Animal Health Inc, purchased 5,000 shares of common stock on August 12, 2026 for $21.82 per share.
NYSE
Jeffrey N Simmons, PRESIDENT, CEO AND DIRECTOR and a Director of Elanco Animal Health Inc, received 128 shares of common stock on August 7, 2026.
NYSE
Robert M Vanhimbergen, EVP and CFO of Elanco Animal Health Inc, purchased 4,200 shares of common stock on August 7, 2026 for $23.08 per share.
NYSE
Rajeev A. Modi, SEE REMARKS of Elanco Animal Health Inc, received 67 shares of common stock on August 7, 2026.
NYSE
Paul Herendeen, a Director of Elanco Animal Health Inc, purchased 10,000 shares of common stock on August 7, 2026 for $23.68 per share.
NYSE
Jeffrey N Simmons, PRESIDENT, CEO AND DIRECTOR and a Director of Elanco Animal Health Inc, received 113 shares of common stock on July 24, 2026.
NYSE
Rajeev A. Modi, SEE REMARKS of Elanco Animal Health Inc, received 59 shares of common stock on July 24, 2026.
NYSE
Robert M Vanhimbergen, EVP and CFO of Elanco Animal Health Inc, received 8 shares of common stock on July 24, 2026.
NYSE
Jeffrey N Simmons, PRESIDENT, CEO AND DIRECTOR and a Director of Elanco Animal Health Inc, received 114 shares of common stock on July 10, 2026.
NYSE
Rajeev A. Modi, SEE REMARKS of Elanco Animal Health Inc, received 60 shares of common stock on July 10, 2026.
NYSE
Elanco Animal Health Inc. reports a transaction by its EVP and CFO, Robert M. VanHimbergen, involving the acquisition of common stock.
NYSE
David S. Kinard, an executive at Elanco Animal Health Inc., was granted stock options with a vesting schedule spanning three years.
NYSE
Director Kapila K. Anand has elected to defer her director cash retainer fees into Elanco Animal Health Inc. stock units.
NYSE
Jeffrey N. Simmons, President, CEO, and Director of Elanco Animal Health Inc., reported a transaction involving deferred stock units.
NYSE
Robert M. VanHimbergen, EVP and CFO of Elanco Animal Health Inc., reported a transaction involving deferred stock units.
NYSE
Robert M. VanHimbergen, EVP and CFO of Elanco Animal Health Inc., reported a transaction involving deferred stock units.
NYSE
Elanco Animal Health CEO Jeffrey N. Simmons acquired 116.9603 deferred stock units on June 12, 2026, valued at $24.17 per unit.
NYSE
Rajeev A. Modi, Executive Vice President at Elanco Animal Health, reported a transaction involving deferred stock units on June 12, 2026.
NYSE
Elanco Animal Health EVP and CFO, Robert M. VanHimbergen, reported a transaction involving deferred stock units on May 29, 2026.
NYSE
Rajeev A. Modi of Elanco Animal Health reports a transaction involving deferred stock units, settling 61,9258 units on May 29, 2026.
NYSE
Jeffrey N. Simmons, CEO of Elanco Animal Health, reported a transaction involving deferred stock units on May 29, 2026.
NYSE
Denise Scots-Knight, a Director at Elanco Animal Health Inc., reported the acquisition of deferred stock units and restricted stock units on May 21, 2026.
NYSE
Lawrence Kurzius, a Director at Elanco Animal Health Inc., received deferred stock units and restricted stock units on May 21, 2026, as part of annual equity awards.
NYSE
Kirk P. McDonald, a Director at Elanco Animal Health Inc., received deferred stock units and restricted stock units as part of annual equity awards.
NYSE
Elanco Animal Health Inc. reports on equity awards granted to its non-employee directors, including deferred stock units and restricted stock units.
NYSE
Deborah Turner Kochevar, a Director at Elanco Animal Health Inc., was granted deferred stock units as part of an annual equity award.
NYSE
R. David Hoover, a Director at Elanco Animal Health Inc., received a grant of deferred stock units as part of an annual equity award.
NYSE
Michael J. Harrington, a Director at Elanco Animal Health Inc., received deferred stock units and restricted stock units as part of annual equity awards.
NYSE
Elanco Animal Health Inc. reports that Director Anand Kapila acquired shares through grants of deferred and restricted stock units.
NYSE
Stacey Ma, a Director at Elanco Animal Health Inc., has reported the acquisition of deferred stock units and restricted stock units.